loading
Precedente Chiudi:
$3.955
Aprire:
$4
Volume 24 ore:
2.99M
Relative Volume:
0.70
Capitalizzazione di mercato:
$818.56M
Reddito:
$35.54M
Utile/perdita netta:
$-59.14M
Rapporto P/E:
-10.34
EPS:
-0.3637
Flusso di cassa netto:
$-80.19M
1 W Prestazione:
-1.57%
1M Prestazione:
+29.21%
6M Prestazione:
-13.56%
1 anno Prestazione:
+44.62%
Intervallo 1D:
Value
$3.62
$4.02
Intervallo di 1 settimana:
Value
$3.62
$4.02
Portata 52W:
Value
$1.72
$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Nome
Cytomx Therapeutics Inc
Name
Telefono
650.515.3185
Name
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Dipendente
69
Name
Cinguettio
@cytomxinc
Name
Prossima data di guadagno
2026-08-06
Name
Ultimi documenti SEC
Name
CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CTMX icon
CTMX
Cytomx Therapeutics Inc
3.76 818.56M 35.54M -59.14M -80.19M -0.3637
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
485.39 123.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
664.52 69.67B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.62 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
298.76 39.89B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
186.88 39.73B 742.00K -1.37B -1.07B -7.0731

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-16 Aggiornamento JP Morgan Neutral → Overweight
2026-01-20 Iniziato Guggenheim Buy
2025-09-22 Iniziato Cantor Fitzgerald Overweight
2025-09-17 Ripresa Barclays Overweight
2025-07-31 Iniziato Oppenheimer Outperform
2025-05-15 Aggiornamento H.C. Wainwright Neutral → Buy
2025-04-14 Ripresa Piper Sandler Overweight
2024-05-28 Aggiornamento Piper Sandler Neutral → Overweight
2024-05-09 Aggiornamento Wedbush Neutral → Outperform
2024-05-06 Aggiornamento Jefferies Hold → Buy
2024-04-22 Aggiornamento JP Morgan Underweight → Neutral
2022-11-14 Downgrade BMO Capital Markets Outperform → Market Perform
2022-07-07 Downgrade Jefferies Buy → Hold
2022-07-07 Downgrade Mizuho Buy → Neutral
2022-07-07 Downgrade Piper Sandler Overweight → Neutral
2022-07-07 Downgrade Wedbush Outperform → Neutral
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-01-18 Aggiornamento Barclays Underweight → Overweight
2021-11-15 Iniziato BTIG Research Buy
2021-05-28 Downgrade Barclays Equal Weight → Underweight
2021-03-29 Iniziato JP Morgan Overweight
2021-03-23 Aggiornamento Jefferies Hold → Buy
2020-09-22 Downgrade Guggenheim Buy → Neutral
2020-06-01 Downgrade Jefferies Buy → Hold
2020-05-14 Reiterato H.C. Wainwright Buy
2020-03-24 Aggiornamento Wedbush Neutral → Outperform
2020-03-04 Iniziato Barclays Equal Weight
2019-11-20 Iniziato Guggenheim Buy
2019-11-11 Downgrade Wedbush Outperform → Neutral
2019-06-13 Iniziato Mizuho Buy
2019-05-14 Iniziato Cantor Fitzgerald Overweight
2019-03-11 Iniziato Barclays Overweight
2018-11-26 Iniziato Piper Jaffray Overweight
2018-10-15 Iniziato Goldman Neutral
2018-09-13 Iniziato H.C. Wainwright Buy
2018-06-01 Iniziato SunTrust Buy
2018-01-05 Iniziato Citigroup Buy
2017-09-08 Iniziato Wedbush Outperform
2017-03-27 Iniziato H.C. Wainwright Buy
2017-03-02 Iniziato Instinet Buy
2017-01-03 Downgrade Oppenheimer Outperform → Perform
2015-11-02 Iniziato Oppenheimer Outperform
Mostra tutto

Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie

pulisher
Jul 09, 2026

CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et

Jul 09, 2026
pulisher
Jul 08, 2026

CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - ad-hoc-news.de

Jul 08, 2026
pulisher
Jul 08, 2026

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance

Jul 08, 2026
pulisher
Jul 07, 2026

CytomX Therapeutics focuses on its antibody-drug conjugate platform - ad-hoc-news.de

Jul 07, 2026
pulisher
Jul 05, 2026

Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance

Jul 05, 2026
pulisher
Jul 03, 2026

CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de

Jul 03, 2026
pulisher
Jul 02, 2026

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits

Jul 02, 2026
pulisher
Jun 30, 2026

CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits

Jun 30, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 27, 2026

Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

CTMX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 23, 2026

CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail

Jun 23, 2026
pulisher
Jun 23, 2026

Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India

Jun 23, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics stockholders approve share increases and board elections - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada

Jun 22, 2026
pulisher
Jun 22, 2026

Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Elaine Jones awarded 59,000 stock options at $2.96 strike - Stock Titan

Jun 22, 2026
pulisher
Jun 19, 2026

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - Insider Monkey

Jun 19, 2026
pulisher
Jun 18, 2026

CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

CytomX CFO Ogden sells $4,953 in company stock By Investing.com - Investing.com South Africa

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX CFO Ogden sells $4,953 in company stock - Investing.com

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026

Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$56.43
price down icon 2.64%
$115.61
price down icon 2.24%
$35.97
price down icon 2.28%
$68.27
price down icon 10.83%
ONC ONC
$298.70
price down icon 1.36%
$186.88
price down icon 2.22%
Capitalizzazione:     |  Volume (24 ore):